New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Bella Mehta bella_mehta
2 months ago
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow.
Average age 28! 87%female, only 7 % with psychiatric referral!
Retrospective 15 pts. https://t.co/241SE6O395
Mrinalini Dey DrMiniDey
2 months ago
#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh
sheila RHEUMarampa
2 months ago
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesn’t really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
Mrinalini Dey DrMiniDey
2 months ago
#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0
Bella Mehta bella_mehta
2 months ago
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta bella_mehta
2 months ago
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Mrinalini Dey DrMiniDey
2 months ago
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
Jiha Lee JihaRheum
2 months ago
Catching your breath session at #EULAR2026
RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr)
Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks)
@RheumNow https://t.co/V1JXM3i9wP
Dr. John Cush RheumNow
2 months ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment
Dr. John Cush RheumNow
2 months ago
EULAR 2026: Industry Press Releases
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will https://t.co/2czkdWKtEO
Bella Mehta bella_mehta
2 months ago
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026
Presence on leucocytes- change from pro inflammatory to anti inflammatory casade
Also in fibroblasts in rheumatoid arthritis.
Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv
Mrinalini Dey DrMiniDey
2 months ago
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
2 months ago
#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio
sheila RHEUMarampa
2 months ago
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
